STOCK TITAN

Gilead Sciences, Inc. - GILD STOCK NEWS

Welcome to our dedicated news page for Gilead Sciences (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gilead Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gilead Sciences's position in the market.

Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) to present new data at San Antonio Breast Cancer Symposium 2023 supporting the use of Trodelvy in certain metastatic triple-negative breast cancer and pre-treated HR+/HER2- metastatic breast cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
-
Rhea-AI Summary
Gilead Sciences, Inc. (GILD) aims to end the HIV epidemic globally through community partnerships and innovative medicines. The company collaborates with organizations like GNP+, UNAIDS, and PEPFAR to expand access to care in low- and middle-income countries. Gilead operates in over 35 countries and is headquartered in Foster City, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
-
Rhea-AI Summary
Gilead Sciences (GILD) Director of Community Health Access and Relations, Claudia Hardy, is working to bring cancer resources and preventive care to underserved communities in Alabama. As the director of Community Health Access and Relations for the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Claudia's personal experience growing up in a medically underserved area and a food desert gives her a unique understanding of the barriers to cancer care in rural areas. She aims to address the lack of transportation, medical lingo comprehension, and access to comprehensive treatment in these communities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
none
Rhea-AI Summary
Gilead (GILD) & Arcellx (ACLX) expand collaboration for CART-ddBCMA & ARC-SparX program ACLX-001. Kite exercises option to negotiate license for ARC-SparX program ACLX-001 in multiple myeloma. Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment. The collaboration aims to bring potentially best-in-class cell therapy to patients, expanding opportunities in lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
partnership
-
Rhea-AI Summary
Gilead (GILD) & Arcellx (ACLX) expand collaboration for CART-ddBCMA & ARC-SparX program ACLX-001. Kite exercises option to negotiate license for ARC-SparX program ACLX-001 in multiple myeloma. Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment. The collaboration aims to bring potentially best-in-class cell therapy to patients, expanding opportunities in lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
partnership
-
Rhea-AI Summary
Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), have expanded their collaboration, with Kite investing $200M at $61.68 per share and an $85 million upfront cash payment. Kite exercised its option to Arcellx's ARC-SparX program ACLX-001 in multiple myeloma and expanded the collaboration to include lymphomas. This investment is anticipated to extend Arcellx's cash runway into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
partnership
Rhea-AI Summary
Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), have expanded their collaboration, with Kite investing $200M at $61.68 per share and an $85 million upfront cash payment. Kite exercised its option to Arcellx's ARC-SparX program ACLX-001 in multiple myeloma and expanded the collaboration to include lymphomas. This investment is anticipated to extend Arcellx's cash runway into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
partnership
-
Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq:GILD) - Gilead Recognized as Top Funder of Health Equity Programs for BIPOC and LGBTQ+ Communities
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
-
Rhea-AI Summary
Gilead Sciences: Research Scholars Program Supports Early-Career Investigators Focused on Advancing Scientific Knowledge in HIV Research, Fueling HIV Research Through the Program, Addressing Unmet Needs in HIV Research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
none
Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) executives to speak at investor conferences. Live webcasts and replays available on investors.gilead.com. Key SEO terms: Gilead Sciences, investor conferences, webcasts, replays, GILD stock, Jefferies London Healthcare Conference, Evercore ISI HealthCONx Conference, Piper Sandler Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
conferences
Gilead Sciences, Inc.

Nasdaq:GILD

GILD Rankings

GILD Stock Data

91.25B
1.24B
0.1%
88.53%
1.55%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Foster City

About GILD

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.